Ann Gils

522 total citations
42 papers, 333 citations indexed

About

Ann Gils is a scholar working on Genetics, Epidemiology and Immunology. According to data from OpenAlex, Ann Gils has authored 42 papers receiving a total of 333 indexed citations (citations by other indexed papers that have themselves been cited), including 36 papers in Genetics, 24 papers in Epidemiology and 16 papers in Immunology. Recurrent topics in Ann Gils's work include Inflammatory Bowel Disease (35 papers), Microscopic Colitis (22 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Ann Gils is often cited by papers focused on Inflammatory Bowel Disease (35 papers), Microscopic Colitis (22 papers) and Immunodeficiency and Autoimmune Disorders (13 papers). Ann Gils collaborates with scholars based in Belgium, Slovenia and Netherlands. Ann Gils's co-authors include Séverine Vermeire, Vera Ballet, Niels Vande Casteele, Gert Van Assche, Paul Rutgeerts, Griet Compernolle, Maja Noman, Geert D’Haens, Evelien Humblet and Christophe Claessens and has published in prestigious journals such as Gastroenterology, Gut and Journal of Crohn s and Colitis.

In The Last Decade

Ann Gils

40 papers receiving 328 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ann Gils Belgium 9 290 202 137 44 38 42 333
D. Coscas Israel 8 325 1.1× 241 1.2× 228 1.7× 52 1.2× 80 2.1× 11 440
Phillip Minar United States 12 317 1.1× 207 1.0× 215 1.6× 33 0.8× 84 2.2× 40 434
Mélanie Rinaudo-Gaujous France 8 327 1.1× 231 1.1× 175 1.3× 92 2.1× 73 1.9× 15 487
Renata Villela Canada 3 459 1.6× 356 1.8× 242 1.8× 49 1.1× 67 1.8× 3 521
Warren Bao United States 2 401 1.4× 296 1.5× 239 1.7× 63 1.4× 60 1.6× 4 503
Edouard Louis Belgium 6 205 0.7× 152 0.8× 88 0.6× 22 0.5× 68 1.8× 21 268
Dhiman Basu United States 5 138 0.5× 157 0.8× 77 0.6× 55 1.3× 58 1.5× 7 304
Greet Claessens Belgium 5 209 0.7× 133 0.7× 101 0.7× 39 0.9× 69 1.8× 11 277
Sue P. Irwin Canada 7 495 1.7× 377 1.9× 221 1.6× 73 1.7× 135 3.6× 8 613
Gert A. Van Assche Belgium 8 290 1.0× 218 1.1× 78 0.6× 30 0.7× 84 2.2× 83 330

Countries citing papers authored by Ann Gils

Since Specialization
Citations

This map shows the geographic impact of Ann Gils's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ann Gils with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ann Gils more than expected).

Fields of papers citing papers by Ann Gils

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ann Gils. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ann Gils. The network helps show where Ann Gils may publish in the future.

Co-authorship network of co-authors of Ann Gils

This figure shows the co-authorship network connecting the top 25 collaborators of Ann Gils. A scholar is included among the top collaborators of Ann Gils based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ann Gils. Ann Gils is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Liefferinckx, Claire, Bram Verstockt, Ann Gils, et al.. (2019). Mo1910 – Long-Term Clinical Efficacy of Ustekinumab in Refractory Crohn’s Disease: A Multi-Centre Belgian Cohort Study. Gastroenterology. 156(6). S–882.
3.
Verstockt, Bram, Maja Noman, Isolde Aerden, et al.. (2018). Mo1880 - Ustekinumab Induces Limited Mucosal Healing after 6 Months in a Real-Life, Prospective Cohort of Patients with Refractory Crohn's Disease. Gastroenterology. 154(6). S–836. 2 indexed citations
4.
Paul, Stéphane, G. Duru, Annick de Vries, et al.. (2017). P226 Comparison of four different immunoassays for measuring golimumab and anti-golimumab antibody concentration in patients with ulcerative colitis. Journal of Crohn s and Colitis. 11(suppl_1). S192–S192. 2 indexed citations
5.
Pouillon, Lieven, Marc Ferrante, Gert A. Van Assche, et al.. (2017). Correlation of Durability of Response, Serum Trough Concentrations and Outcome Parameters: Long-Term Follow-up of the Trough Concentration Adapted Infliximab Treatment (TAXIT) Trial. Gastroenterology. 152(5). S39–S39. 1 indexed citations
6.
Billiet, Thomas, Isabelle Cleynen, Marc Ferrante, et al.. (2016). A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-tumour necrosis factor serum levels in inflammatory bowel disease. 10. 2 indexed citations
7.
Stappen, Thomas Van, L. Bollen, Niels Vande Casteele, et al.. (2016). Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with ulcerative colitis. 10. 1 indexed citations
8.
Stappen, Thomas Van, Niels Vande Casteele, Nick Geukens, et al.. (2016). 697 Analytical and Clinical Validation of a Rapid Point-of-Care Assay for Infliximab Quantification in Patients With Ulcerative Colitis. Gastroenterology. 150(4). S145–S145. 1 indexed citations
9.
Gils, Ann, et al.. (2015). The biosimilars of infliximab are equally well quantified in a clinically validated infliximab assay. 9. 4 indexed citations
10.
Casteele, Niels Vande, Diane R. Mould, Ann Gils, et al.. (2015). Tu1308 Adequate Trough Concentrations and Sustained TNF Suppression Early on During Induction Therapy With Adalimumab Predict Remission in Anti-TNF Naïve Crohn's Disease Patients. Gastroenterology. 148(4). S–854. 2 indexed citations
11.
Papamichael, Konstantinos, Niels Vande Casteele, Thomas Billiet, et al.. (2015). Tu1286 Early Therapeutic Drug Monitoring for Prediction of Short-Term Mucosal Healing in Patients With Ulcerative Colitis Treated With Infliximab. Gastroenterology. 148(4). S–848. 2 indexed citations
12.
Casteele, Niels Vande, Marc Peeters, Marc Ferrante, et al.. (2014). P484 Functional cellular based assay reveals neutralising anti-drug antibodies in IBD patients treated with maintenance adalimumab. Journal of Crohn s and Colitis. 8. S268–S269. 1 indexed citations
13.
Casteele, Niels Vande, Ann Gils, Vera Ballet, et al.. (2013). Randomised Controlled Trial of Drug Level Versus Clinically Based Dosing of Infliximab Maintenance Therapy in IBD: Final Results of the TAXIT Study. United European Gastroenterology Journal. 1. 27 indexed citations
14.
Ferrante, Marc, M. Arias, Séverine Vermeire, et al.. (2013). Su1204 Long-Term Outcome of Infliximab Therapy in Patients With Ulcerative Colitis: Identification of Predictors of Relapse-Free and Colectomy-Free Survival. Gastroenterology. 144(5). S–426. 3 indexed citations
15.
Casteele, Niels Vande, Griet Compernolle, Vera Ballet, et al.. (2012). OP11 Individualised infliximab treatment using therapeutic drug monitoring: A prospective controlled Trough level Adapted infliXImab Treatment (TAXIT) trial. Journal of Crohn s and Colitis. 6. S6–S6. 32 indexed citations
16.
Casteele, Niels Vande, Griet Compernolle, Vera Ballet, et al.. (2012). 1159 Results on the Optimisation Phase of the Prospective Controlled Trough Level Adapted Infliximab Treatment (TAXIT) Trial. Gastroenterology. 142(5). S–211. 39 indexed citations
17.
Drobne, David, Peter Bossuyt, Christine Breynaert, et al.. (2011). Long term evolution and impact of immunomodulator cotreatment and withdrawal on infliximab on trough levels in 223 patients with Crohn's disease. Open Repository and Bibliography (University of Liège). 2 indexed citations
18.
Baert, Filip J., David Drobne, Vera Ballet, et al.. (2011). Early Trough Levels and Antibodies Predict Safety and Success of Restarting Infliximab After Long Drug Holiday. Gastroenterology. 140(5). S–62. 5 indexed citations
19.
Arias, M., Isabelle Cleynen, Karolien Claes, et al.. (2011). The Role of FC Gamma Receptor (FCGR) Mutations in the Response to Infliximab in Inflammatory Bowel Disease. Gastroenterology. 140(5). S–1. 2 indexed citations
20.
Assche, Gert Van, Séverine Vermeire, Vera Ballet, et al.. (2011). Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial. Gut. 61(2). 229–234. 102 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by D. Coscas Breakdown of academic impact, for papers by Phillip Minar Breakdown of academic impact, for papers by Mélanie Rinaudo-Gaujous Breakdown of academic impact, for papers by Renata Villela Breakdown of academic impact, for papers by Warren Bao Breakdown of academic impact, for papers by Edouard Louis Breakdown of academic impact, for papers by Dhiman Basu Breakdown of academic impact, for papers by Greet Claessens Breakdown of academic impact, for papers by Sue P. Irwin Breakdown of academic impact, for papers by Gert A. Van Assche
Rankless by CCL
2026